CD47 blockade augmentation of trastuzumab antitumor efficacy dependent on antibody-dependent cellular phagocytosis

The HER2-specific monoclonal antibody (mAb), trastuzumab, has been the mainstay of therapy for HER2(+) breast cancer (BC) for approximately 20 years. However, its therapeutic mechanism of action (MOA) remains unclear, with antitumor responses to trastuzumab remaining heterogeneous and metastatic HER...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:JCI Insight
Κύριοι συγγραφείς: Tsao, Li-Chung, Crosby, Erika J., Trotter, Timothy N., Agarwal, Pankaj, Hwang, Bin-Jin, Acharya, Chaitanya, Shuptrine, Casey W., Wang, Tao, Wei, Junping, Yang, Xiao, Lei, Gangjun, Liu, Cong-Xiao, Rabiola, Christopher A., Chodosh, Lewis A., Muller, William J., Lyerly, Herbert Kim, Hartman, Zachary C.
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: American Society for Clinical Investigation 2019
Θέματα:
Research Article
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6975273/
https://ncbi.nlm.nih.gov/pubmed/31689243
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.131882
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια